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Abstract 
In a number of Drosophila models of genetic Parkinsons Disease (PD) flies 
climb more slowly than wild-type controls. However, this assay does not 
distinguish effects of PD related genes on gravity sensation, arousal, central 
pattern generation of leg movements or muscle. To address this problem, we 
have developed an assay for the fly proboscis extension response (PER). This 
is attractive because the PER has a simple, well-identified reflex neural circuit, 
in which sucrose sensing neurons, activate a pair of command interneurons, 
and thence motoneurons whose activity contracts the proboscis muscle. This 
circuit is modulated by a single dopaminergic neuron (TH-VUM).  
We find that expressing either the G2019S or I2020T (but not R1441C, or 
kinase dead) forms of human LRRK2 in dopaminergic neurons reduces the 
percentage of flies that initially respond to sucrose stimulation. This is 
rescued fully by feeding L-DOPA and partially by feeding kinase inhibitors, 
targeted to LRRK2 (LRRK2-IN-1 and BMPPB-32). High-speed video shows 
that G2019S expression in dopaminergic neurons slows the speed of proboscis 
extension, makes its duration more variable, and increases the tremor. Testing 
subsets of dopaminergic neurons suggests that the single TH-VUM neuron is 
likely most important in this phenotype.  
We conclude the Drosophila PER provides an excellent model of LRRK2 motor 
deficits showing bradykinesia, akinesia, hypokinesia and increased tremor, 
with the possibility to localise changes in neural signalling. 
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Introduction 
Parkinsons Disease is a progressive neurodegenerative condition 
characterised by pathological loss of dopaminergic neurons in the substantia 
nigra.  The reduction in dopamine in the projections to the striatum leads to a 
range of motor disorders, characterised by bradykinesia (slower movements), 
hypokinesia (a reduction in the amplitude of movements) akinesia (absence of 
movement altogether) and tremor.  
Although the cause of the majority of Parkinsons disease is unknown, a small 
proportion is inherited (see, for review, Singleton et al., 2013) with the most 
common genetic form being due to mutations in LRRK2 (Leucine Rich Repeat 
Kinase 2).  
This gene is translated into a large, multi-domain protein, and the pathogenic 
mutations include G2019S and I2020T 2, in which the kinase activity is 
increased 3, and R1441C, a mutation in which the GTPase activity is thought 
to be reduced 4. 
The excellent genetic toolkit provided by Drosophila led to the creation of fly 
models of Parkinsons disease. These reflect many features of the disease (loss 
of dopaminergic neurons, reduced movement, mitochondrial abnormalities, 
oxidative stress and visual deficits 5,6. Many labs have adopted the fly 
negative geotaxis assay (sometimes called the startle response assay) as their 
measure of movement 79. In this, the speed at which flies walk up a glass 
cylinder in response to a sharp tap is recorded. Although PD-mimic flies have 
reduced movement, it is hard to specify exactly where the changes are taking 
place (response to the startle stimulus or gravity, or effects on the central 
pattern generator or motor neurons or changes directly affecting the leg 
muscles themselves). This assay also fails to discriminate between the 
different possible movement defects (akinesia, hypokinesia and bradykinesia). 
We suggest the requirement for another, simpler assay system. 
This is reinforced by the difficulty of determining which of the ~125 
dopaminergic neurons in the fly CNS 10,11, are important in the negative 
geotaxis response.  Although dopaminergic innervation of the mushroom 
body by 15 PAM neurons plays a major role in this negative geotaxis 
response 12, the subsequent neuronal pathway is unclear. Further, 
manipulations of PD-related transgenes often lead to the loss of a relatively 
small proportion of dopaminergic neurons, with many clusters remaining 
unaffected.  For example, with the LRRK2-G2019S mutation, the Protocerebral 
Posterior Medial (PPM) cluster dropped from 14 to 12 dopaminergic neurons 
but the Protocerebral Anterior Lateral (PAL) cluster remained unaffected 13.  
Throughout the literature, the multiple processes involved in slowed negative 
geotaxis combined with the observed small loss of dopaminergic neurons act 
to obscure the functional relationship.  To progress, we need to link a precise 
measurement of movement with the physiology of a few specific 
dopaminergic neurons. 
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An exciting solution to this problem is provided by the discovery that a single 
dopaminergic neuron strongly modulates the fly Proboscis Extension 
Response (PER) 14.   
As a fly walks into a solution containing sucrose, the Gr5a chemosensory cells 
on its front legs are activated (Fig. 1, step 1).  Their axons project to the sub-
esophageal zone of the CNS (SEZ; the part signalling the taste response, Fig. 1, 
step 2). Within the SEZ, the chemosensory inputs activate the interneuronal 
pathway 15, leading to the pharyngeal E49 motoneurons, whose action 
potentials elicit contraction of the M9 muscle (Fig. 1, step 3). This well 
characterised neuronal pathway results in the reflex extrusion of the 
proboscis towards the food (Fig. 1, step 4), allowing the fly to ingest the 
solution. Although the sensory and motor steps in this pathway have been 
well defined (see for review Freeman and Dahanukar, 2015; or McKellar, 
2016), the interneuronal steps mostly remain to be described. 
One well-defined neuron that modulates the PER is TH-VUM, a single, 
unpaired neuron in the SEZ, which makes output synapses onto the sense 
cells and interneurons 14,18,19 (Fig. 1). Strong activity in the TH-VUM leads to 
contraction of the proboscis muscle; blocking the output of the TH-VUM 
reduces the probability of a sucrose-induced PER. The frequency of action 
potentials in the TH-VUM correlates with the length of starvation 14. 
Interestingly, the TH-VUM fires steadily in a way reminiscent of mammalian 
substantia nigra dopaminergic neurons 20.   
We have now found that expression of LRRK2-G2019S, the most common 
cause of genetic Parkinsons disease, in dopamine neurons results in a 
reduced PER, with bradykinesia, akinesia, and tremor, and that this is rescued 
by L-DOPA or by kinase inhibitors targeted at LRRK2.  
Results 
Upregulation of LRRK2 kinase activity in dopaminergic neurons causes 
akinesia 
In order to test the neuronal specificity of the PD-related mutation LRRK2-
G2019S, we first expressed this in each of the components of the PER reflex 
pathway, recording the proportion of a population of starved flies that 
extended their proboscis in response to a moderate (100 mM) sugar stimulus 
(Fig. 2A, B). Strikingly, when we expressed LRRK2-G2019S in the 
dopaminergic neurons with TH-GAL4 (tyrosine hydoxylase GAL4), the 
proportion of young flies responding was about half that of control genotypes 
(no-transgene expressed, χ2-post-hoc test, p<0.001; to 76 to 35 %, Fig.2A). The 
same result was seen in a second sample, where the proportion of TH > 
G2019S flies responding was also less than half that of the wild-type (Fig. 2B). 
In contrast, there was no effect of G2019S when driven in all neurons (nSyb-
GAL4, p=0.17), or in just the sensory neurons (Gr5a-GAL4, p=0.11) or solely in 
proboscis motoneurons (E49-GAL4, p=0.21).   
In order to establish if this was specific for the G2019S mutation, we also 
tested a second PD-related mutation in which kinase activity is increased 
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(I2020T), a mutation in the GTPase domain (R1441C), a kinase dead form 
(LRRK2-G2019S-K1906M) and the normal human form (hLRRK2). Of these, 
only dopaminergic expression of I2020T had any specific effect, reducing the 
proportion of flies that responded from 61 to 35 % (χ2-post-hoc test, p< 0.001, 
Fig. 2B). We did note a general reduction on all flies containing the hLRRK2 
(Fig. 2A,B), due perhaps to the increased expression levels of this gene (Fig. 
2C). In turn, the lack of effect of TH > R1441C might be due to the weaker 
expression (Fig. 2C), based on our hypothesis that the impact of any one 
LRRK2 mutant on PER is correlated with the level of LRRK2 protein 
production in the dopaminergic neurons.  
We tested a second set of independently generated LRRK2 transgenic flies 21, 
and found the same: only 36% of TH > G2019S flies responded compared with 
52 % of TH > hLRRK2 and 61 % of TH/+ (χ2-post-hoc test, G2019S v hLRRK2 
p=0.04; G2019S v wild-type p=0.0034).   
To determine if the PER response was age dependent, we tested flies from 3 
days to over 18 days, and found none of the genotypes showed any age 
dependent change (Fig. 2C). Dopaminergic expression of G2019S or I2020T 
reduced the proportion of flies responding to the sucrose stimulus at all ages. 
We found no effect of genotype on mass at 20 days (non-transgene control v 
TH > hLRRK2 v TH > G2019S, F2,26 df = 0.003, p=0.99), suggesting the reduced 
frequency of PER seen in starved flies was not preventing them from  
increasing their mass when provided with food ad libitum. However, by 28 
days, only 57 % of flies were alive, with increased mortality in each of the TH 
> hLRRK2, TH > G2019S and TH > I2020T compared to the TH/+ control (χ2-
post-hoc test, p < 0.01 for each; survival 38, 53, 57, 80% respectively).    
These experiments show that the expression of high kinase forms of LRRK2 
reduces the proportion flies showing PER, i.e. they show akinesia.   
Rescue of akinesia by L-DOPA and kinase inhibitors 
Since the standard symptomatic treatment for Parkinsons Disease is L-DOPA, 
we tested if this compound would rescue the PER deficit induced by 
dopaminergic expression of G2019S or I2020T. In both cases, the 
administration of L-DOPA to the adult flies raised the proportion of flies that 
respond to sucrose to control levels (Fig. 3A). This was not due to an increase 
in general responsiveness, because we saw no effect of L-DOPA on the flies 
expressing hLRRK2, KD or R1441C.  
As the most common form of genetic Parkinsons disease is caused by the 
LRRK2-G2019S mutation, with its increased kinase activity, a promising 
therapy would be to deploy kinase inhibitors targeted at LRRK2. The first of 
these to be developed was LRRK2-IN-1 22. Application of 2.5 µM LRRK2-IN-1 
partially rescued the frequency of PER responses, from 32 to 47 % (p=0.002, 
Fig. 3B). Since LRRK2-IN-1 has off-target effects, in vitro 23,24 and in vivo 6, we 
next tested the more specific compound BMPPB-32, which also gave a partial 
rescue, to 44% (Fig.3B).  The proportion of flies showing the PER was the 
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same for LRRK2 and BMPPB-32 (p=0.077) and both were below the wild-type 
level (73 %).    
We conclude that drugs targeted at LRRK2 ameliorate the reduced PER 
response of TH > G2019S flies.  
Dopaminergic expression of LRRK2-G2019S slows movement and increases 
tremor in the PER 
For TH > G2019S flies showing a PER, recordings were made using a camera 
with high frame rate (200 / second), and digitised the distance from the eye to 
the end of the proboscis, to measure the movement during the PER. 
Individual traces showed that some TH > G2019S flies had very slow PER, 
taking 3 or even 4 times longer than the median wild-type control (Fig. 4A), 
with the increase in standard error being very noticeable (Fig. 4B). A second 
mutant, I2020T, also showed a slower PER (Fig. 4 Bii). For both TH > G2019S 
and TH > I2020T flies, the speed of the PER is fully rescued to wild-type by 
feeding 2.5 µM BMPPB-32.   
Using the independently G2019S and hLRRK2 lines 21, we also found a slower 
PER with TH > G2019S. In this case the duration of the PER increased from 
0.30 ± 0.025 s (TH/+) to 0.57 ± 0.11 s (TH > G2019S) (mean ± SE, Tukey post-
hoc test, p=0.017). The TH > hLRRK2 was the same as TH/+ (p=0.81).   
Additionally, it appeared that the TH > G2019S traces were more irregular. To 
assess this quantitatively, each trace was fitted by a smooth curve (a piecewise 
cubic spline), and the deviation of the actual trace from smoothed determined 
(Fig. 4Ci). This showed that the TH > G2019S flies had a much longer path, 
about twice that of the control flies. The proboscis does not move out in a 
smooth trajectory, but oscillates, showing tremor.  No such changes were seen 
in the TH > hLRRK2 flies; they were the same as the no-transgene cross (Fig. 
4Cii). 
Thus dopaminergic expression of LRRK2-G2019S induces bradykinesia and 
tremor as well as akinesia. 
The single dopamine neuron (TH-VUM) is mainly responsible for akinesia 
Our next step was to test which dopaminergic neurons are responsible for 
akinesia in the PER response, focusing on the difference between flies with 
increased kinase activity (G2019S or I2020T) and the kinase dead (KD) line.  
There are eight clusters of dopaminergic neurons in the fly CNS (Fig. 5B), and 
a range of GAL4 drivers have been developed to target various subsets of 
these. We started with a GAL4 driver DDC 25, which has been widely used for 
studies of negative geotaxis and which gives generalised dopaminergic 
neuron expression, as well as expressing in serotonergic neurons. As with the 
TH-GAL4 (Fig. 1), fewer flies expressing G2019S or I2020T with DDC showed 
the PER compared with those flies expressing LRRK2-KD (Fig. 5). We next 
tested HL9 26 which expresses in all the dopaminergic neurons except for the 
PAL cluster (Fig. 5B), though it may only label a proportion of each cluster. It 
may also label a few non-dopaminergic neurons (Fig. 5C). Again, the G2019S 
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and I2020T flies were less responsive than the KD flies. With the C-GAL4 line 
27, which expresses in all dopaminergic neurons except the PPM3 and PPL1 
clusters, we saw the same pattern: G2019S and I2020T flies showed less PER 
than the KD flies. All these GAL4 lines express in the VUM dopaminergic 
neurons. The final GAL4 tested, D 27  expresses in all dopaminergic neurons 
except the PAL, PPL2 and does not express strongly in the VUM neurons. 
Remarkably, with the D-GAL4, flies expressing G2019S, I2020T and KD 
forms of LRRK2 all showed an equal response to sucrose, strikingly different 
from all the other dopaminergic GAL4s.  
We next used a nuclear GFP (eIfGFP Fig. 5C) to confirm the expression 
pattern of the GAL4 lines in the SEZ. DDC, HL9 and C all showed a group of 
three GFP-positive neurons located posteriorly plus a fourth cell anteriorly. 
One of the three posterior cells is the unpaired midline TH-VUM and the 
other two are descending neurons (left and right DA-DNs), whose activity 
represents leg movements 28. The D > eIfGFP fluorescence pattern is 
noticeably different: only the anterior cell shows any GFP signal (and that 
weakly), but the three posterior neurons not being labelled at all. The 
presence of the three posterior neurons is confirmed by the anti-TH staining. 
Consequently, we suggest that the effect of expressing LRRK2-G2019S in 
dopaminergic neurons is mostly mediated by the single TH-VUM neuron, 
because the two descending neurons do not show a direct link to feeding 
behaviour. Only when G2019S is expressed in the TH-VUM do we see the 
reduction in PER, i.e. akinesia. However, we cannot rule out an effect of the 
PPL2 neurons, which also modulate the feeding system29  as they are also not 
targeted by the D-GAL4.  
 
Discussion 
Our principle finding is that expressing LRRK2 forms with increased kinase 
activity (G2019S, I2020T) in sets of dopaminergic neurons that include the TH-
VUM is sufficient to induce akinesia, bradykinesia and tremor in the fly 
proboscis extension response (PER). Although previous work with flies and 
rodents have identified movement disorders in Parkinsons disease models, 
our PER assay uniquely identifies the components of the response, in the 
context of changes mostly due to to a single dopaminergic neuron (TH-VUM).  
A key point is that our PER assay demonstrates dopaminergic-bradykinesia 
even at 3 days. In comparison, data from negative geotaxis (startle-induced 
climbing response) assays of G2019S, I2020T or R1441C transgenics is more 
complex, depending on age and genotype. One report shows that while 
locomotion in DDC>I2020T flies is already compromised at 5 days 30, another 
study shows that TH>I2020T flies show little deficit at any age 31. This may be 
because DDC-GAL4 includes serotonergic, as well as dopaminergic neurons, 
and thus more cells compared with TH-GAL4.  Using DDC-GAL4, to express 
LRRK2 in old (>5 weeks) flies, G2019S and R1441C movement is shown to be 
reduced 32,33, while younger flies show no deficit. In contrast, our data shows 
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movement deficits in young TH > G2019S and TH>I2020T flies, which are 
maintained over the first few weeks of adult life. Indeed, LRRK2 mutations 
already start to affect Drosophila larvae, indicating effects at an earlier 
timepoint 21,34,35.  
One disadvantage of working with older flies is that, by 5 weeks, a proportion 
of flies will have died, potentially those most strongly influenced by the 
transgene, so that negative geotaxis assays may underestimate the real impact 
of LRRK2 mutations. Our assay has the advantage of working at 3 days, 
before flies have started to die, and potentially could be developed so that the 
same individual fly might be tested at different time points. This would 
permit comparison of the individual and population responses. 
In our visual assays with TH > G2019S, we found that 3 day old flies showed 
no detectable visual deficits, though younger flies (1 day old) had overactive 
vision, and old flies (28 day old, or visually stressed) had much reduced 
response 6,36,37. Overactivity has also been reported in young transgenic 
LRRK2 rats, followed later by loss of movement 3840. We have not tested the 
feeding response of flies less than 3 days old, because these newly emerged 
flies rest and expand their cuticle, and are not feeding: this makes them 
unsuitable for PER assay. 
However, the PER of our mildly starved 3-day-old TH > G2019S flies is 
already reduced, and remains well below wild-type levels for at least 18 days. 
A more pronounced PER-deficit might arise in older flies (5 weeks), and/or 
those kept at 29 °C to enhance transgene expression.    
Further, the movement deficits in our PER assay on flies starved for 2-3 hours 
are mainly a consequence of expressing G2019S in a single dopaminergic 
neuron, TH-VUM, rather than the mixed effect of a range of dopaminergic 
clusters.  
In this respect the PER assay differs from both negative geotaxis and our 
visual assay (3 different kinds of dopaminergic neuron are present in the 
retina). However, we note that longer term modulation of feeding appears to 
involve other dopaminergic clusters, interacting in the mushroom bodies 41. 
Additionally, our PER deficit occurs in young flies in which the TH-VUM is 
still present, offering the potential to understand the processes by which 
LRRK2 leads to neuronal silencing in a single identified neuron.   
We find that both the akinesia and bradykinesia components of the TH > 
G2019S effect on PER are dependent on the kinase role of LRRK2. We observe 
no effect of expressing the KD (kinase-dead, G2019S-K1906M) form of LRRK2, 
although the expression level is stronger than G2019S. In this respect, it 
resembles the visual assay, where expressing G2019S, but not this KD 
construct led to retinal neurodegeneration 37.  The TH > R1441C flies also 
showed no reduction in PER, or in visual degeneration 37 though it is possible 
that this is because R1441C is not so effectively expressed. The rescue by the 
specific LRRK2 inhibitor, BMPPB-32, argues that the reduction in PER is a 
consequence of phosphorylation of substrate(s) by LRRK2. We previously 
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showed this inhibitor was effective in a visual assay, reverting TH > G2019S 
phenotypes in both young and old flies 6,36. Another specific inhibitor LDN-
73794 prevents loss of DDC > G2019S induced locomotion in old flies 42. The 
PER assay has an advantage over the climbing assay (startle response), where 
degeneration is usually measured at 4-5 weeks, as our flies only need to be 
fed with the inhibitors for 3 days, reducing compound requirements. 
Genetically activating or silencing the TH-VUM respectively increase or 
decrease the probability of a PER 14. Thus, our data showing kinase active 
LRRK2 transgenes in the TH-VUM reduce PER, could be explained by a 
reduction in dopamine release by this neuron. We hypothesise that 
expressing G2019S in the TH-VUM could lead to either (i) failure of TH-VUM 
neurites to grow, (ii) a reduction in its tonic firing (iii) less dopamine 
synthesis or (iv) lower probability of release of dopamine onto the reflex 
pathway. Cultured mammalian neurons, fly motoneurons and sensory cells 
all have reduced neurites with G2019S 21,43,44. While it is possible that G2019S 
also reduces neuritic branching in the TH-VUM neuron, our data rather 
favours hypotheses (iii) or (iv) since we found that feeding flies L-DOPA 
rescued the TH > G2019S loss of PER. Reduced dopamine levels have been 
reported with DDC > G2019S, and with ubiquitous expression of an increased 
kinase form of the fly homolog dLRRK 45,46. In both Drosophila and mammals, 
L-DOPA can cross the blood-brain barrier (BBB), but dopamine cannot 47. 
Thus we suggest that uptake of L-DOPA into the TH-VUM leads to increased 
dopamine levels and release, rescuing the effect of TH > G2019S. Increasing 
the amount of dopamine released onto the sugar sensing Gr5a neurons would 
then rescue the proportion of flies that show the PER (akinesia), while release 
onto second order, local interneurons, might affect the motoneurons and 
thence speed (bradykinesia), and tremor of the proboscis extension. Such a 
dual output onto Gr5a neurons and onto local interneurons is suggested by 
the fact that 2.5 µM BMPPB-32 fully rescues bradykinesia, but only partially 
rescues akinesia. Although a number of interneurons in the SEZ with roles 
controlling proboscis extension, ingestion, and memory have recently been 
identified (e.g. Cheung et al., 2017; Kim et al., 2017; Yapici et al., 2016), the 
link between Gr5a sense cells and the E49 motoneurons remains to be 
established.   
   
Methods 
Flies, Drosophila melanogaster, were raised at 25 °C on cornmeal-sugar-agar-
yeast food. The following GAL4 lines were used: TH (tyrosine hydoxylase) 
GAL4 51, DDC-GAL4 25, HL9 26 or the C and D-GAL4 stocks 27, the pan-
neuronal nSyb-GAL4 (Stephen Goodwin), the sensory Gr5a-GAL4 and 
motoneuron E49-GAL4 18. The UAS lines were: wild-type hLRRK2 or LRRK2-
G2019S 32, hLRRK2-I2020T and the kinase dead line LRRK2-G2019S-K1906M 
(hereafter, KD) 21, and hLRRK2-R1441C 31; eIfGFP (eIF4AIII::GFP,  Andreas 
Prokop). In some confirmatory experiments, independent LRRK2-G2019S and 
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hLRRK2 lines were used 21. The lab stocks of CS (Canton-S), w1118 (w¯) and 
wapricot (wapr Bloomington stock 148) provided wild-type outcross controls. 
PER (proboscis extension response) was performed (A.C.C.) by collecting 
male flies of known age at the start of the working day, under CO2 anesthesia, 
and sticking them ventral side up to card with rubber cement (Fixo Gum). 
Flies were left to recover for 2-3 hours at 25 °C. They were presented with a 
droplet of 100 mM sucrose solution to the legs, and the immediate PER/no 
PER scored (response in < 2 s). Experiments were designed so that each graph 
plotted here comes from flies scored over 3 adjacent days, with the genotypes 
mixed each day, to allow for the small variations in food and environmental 
conditions. Power calculations indicate that a medium effect size, with a 
sample of 500 flies, and 16 df, would be detected at the 1 % level >98% of the 
time. 
Drugs were fed to adult flies from eclosion until testing. L-DOPA (Sigma) was 
added to food (final concentration 50 µM). BMPPB-32 and LRRK2-IN-1 
(Lundbeck) were dissolved to give a final concentration in the food at 2.5 µM.         
PER was filmed using a Mikrotron MC-1362 camera mounted on a Zeiss 
Stemi microscope.  Videos were acquired at 200 frames/second; sample 
movies for a wild-type and TH > G2019S flies are presented in Movies S1 and 
S2. . Only the first PER of each fly was analyzed. In Matlab, the eye and tip of 
the proboscis were marked and their separation was determined for each 
frame individually. The analyses of Movies S1 and S2 are shown in Movies S3 
and S4, respectively. 
Western Blots were performed as described 6 using the heads of 3-day old 
female flies, raised at 29 °C using anti-LRRK2 (Neuromab, clone N241A/34,, 
1:1000) and anti-β-actin (Proteintech, 1:180000, loading control). The data is 
representative of three blots. 
Immunocytochemistry was as described recently 37, using mouse anti-TH 
(Immunostar, 1:1000)  and driving eIfGFP using the required GAL4 line. All 
data is from male flies, aged 3-5 days. No anti-GFP was used in the data 
chosen for illustration. The brightness and contrast of the images was 
adjusted in ImageJ so that the cells could be seen in both colour channels, as 
each GAL4 drove GFP with a different intensity in the VUM neurons. 
Original images available on request to cje2@york.ac.uk Representative 
data from at least three preparations shown. 
Statistics. For analysis of the proportion of flies showing a PER, statistical 
significance was determined using the χ2-post-hoc test in the Fifer package 
of R. Confidence limits were determined using the Binomial test in R. 
Measurements of the speed of the PER were analyzed by ANOVA and Tukey 
post-hoc tests. For a medium effect size, with 26 flies in each of 3 
samples,and the probability of 0.05, the power is 63%. N values for each 
genotype / treatment are included in Supplementary Table 1.  
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 Figure legends.  
 
Fig. 1. The proboscis extension response (PER) of Drosophila. A. The PER takes 
place when sugar sensitive (Gr5a) neurons on the legs respond (step 1) and 
signal to the sub-esophageal zone of the CNS (SEZ, step 2). This leads to 
activation of the E49 motoneurons for the proboscis extension muscle (step 3), 
muscle contraction (step 4) and extension of the proboscis (step 5). In the sub-
esophageal zone, the neuronal signal is modulated by a dopaminergic neuron, 
TH-VUM, and by other inputs from CNS neurons, possibly including other 
dopaminergic neurons. B. Schematic neural circuit, showing the modulation 
of the sensory neuron  interneuron  motoneuron axis by TH-VUM. Other 
interneurons also modulate the proboscis extension response, as reviewed 
recently 17. A modified after 52,53; B after 14,15,19. 
Fig 2. The PER shows bradykinesia with dopaminergic expression of two 
LRRK2 mutations (G2019S, I2020T) that have increased kinase activity. This 
reduces the proportion of flies that respond to sucrose stimulation with a 
proboscis extension response. A. Comparison of the expression of a 
Parkinsons mutant with upregulated kinase activity (LRRK2-G2019S) with 
wild-type hLRRK2, and a kinase dead line (KD, LRRK2-G2019S-K1906M). 
Each group of bars shows the effect of transgene expression in dopaminergic 
neurons (using the TH GAL4), the sugar sensitive neurons on the legs (Gr5a 
GAL4), in the proboscis motoneurons (E49 GAL4) in relation to outcross 
controls (+) in which no transgene was expressed. N = 1972, at least 60 flies 
per sample. B. Dopaminergic expression of two increased kinase lines 
(G2019S, I2020T) reduces the PER at all ages. There is no decline in the 
proportion of flies showing PER with age, up to 28 days. N = 1839, at least 75 
flies in each sample. C. Western Blot showing that dopaminergic expression 
of hLRRK2 or KD leads to stronger staining than LRRK2-G2019S, while the 
R1441C is slightly weaker. In A & B, wild-type (+) is TH/wa; in C, w¯ and CS. 
Data derived from different flies in A & B. In C, flies were raised together, so 
that the samples derive from the same experiment and were processed in 
parallel. 
Fig. 3. L-DOPA and LRRK2-specific kinase inhibitors both rescue the 
bradykinesia induced by kinase mutations in the PER. A. Feeding 50 µM L-
DOPA rescues the reduction in PER by dopaminergic expression of LRRK2-
G2019S or LRRK2-I2020T to wild-type levels.  L-DOPA has no effect on 
hLRRK2, kinase dead (KD, LRRK2-G2019S-K1906M) or the GTPase mutant 
(R1441C). All transgenes expressed by the TH GAL4. The wild-type (+) is w¯. 
N = 902, at least 60 flies per sample. B. LRRK2 kinase inhibitors rescue the 
reduction in PER caused by dopaminergic expression of LRRK2-G2019S. Flies 
were fed with either 2.5 µM BMPPB-32 or LRRK2-IN-1. Neither drug affects 
the controls or flies with dopaminergic expression of hLRRK2, KD, or R1441C. 
Exact genotypes: +/+ CS/w¯; TH/+ TH GAL4/CS. N = 3387, at least 130 flies 
per sample.  
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Fig. 4. Dopaminergic expression of LRRK2-G2019S (TH GAL4) slows and 
increases tremor in the PER. A. The raw plot of the distance between the eye 
and the tip of the proboscis shows that the PER takes longer, and is more 
variable, with TH > G2019S than with TH > hLRRK2 or the control with no 
transgene expressed (TH/+). B. Summary showing the longer (and more 
variable) time taken by the PER in TH > G2019S and TH > I2020T flies.  
Feeding 2.5 µM BMPPB-32 reverts the time taken to control levels. C. Fitting a 
cubic spline to each trace (i) generates a smooth curve, allowing the 
calculation of the extra path taken by the proboscis. The mean extra path (ii) is 
longer for TH > G2019S than the wild-type or TH > hLRRK2, indicating 
increased tremor. Data for A, Bi and C from the same data set, N = 80, at least 
26 in each group; for Bii N = 141, at least 15 in each group. TH/+ is TH/w¯.  
 
Fig. 5. The presence of dopaminergic TH-VUM neuron is essential for the 
G2019S/I2020T mediated reduction in PER. A. Proportion of flies responding 
when LRRK2 transgenes are expressed in different subsets of the 
dopaminergic neurons, using the DDC, HL9, C or D GAL4 drivers. There is 
no difference between the increased kinase mutants (G2019S/I2020T) and the 
kinase-dead construct (KD, G2019S-K1906M) with the D GAL4, which does 
not express in the TH-VUM neurons. All the other GAL4 lines tested express 
in the TH-VUM neurons and show a smaller response in G2019S/I2020T than 
in KD. Exact genotypes: + is wa. B. Summary maps of the expression patterns 
of the GAL4 drivers used in A. Figures redrawn after Mao and Davis (2009). 
C. The lack of TH-VUM in the D line is confirmed anatomically. Each panel 
shows the projection of a confocal stack through the sub-esophageal zone (as 
marked in the first panel by the dotted box). Neurons marked by expression 
of eIfGFP under the control of the relevant GAL4 and stained by anti-TH 
antibody. The SEZ contains a single anterior cell (a) and a group of 3 
posterior cells (p), marked with anti-TH antibody With DDC, HL9 and C 
GAL4 drivers, all four SEZ neurons were GFP-positive. With D, the nucleus 
of the anterior neuron a has a weak GFP signal, but the 3 posterior neurons 
marked with anti-TH antibody do not fluoresce green (note the cytoplasm of 
the two left posterior cells is merged in this projection of the z-stack, but their 
empty nuclei are still visible). Scalebar 20 µm.  
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